{"id":3879,"date":"2017-02-07T17:00:00","date_gmt":"2017-02-07T23:00:00","guid":{"rendered":"https:\/\/kedrion.lotrek.net\/news\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/"},"modified":"2021-03-08T15:02:00","modified_gmt":"2021-03-08T14:02:00","slug":"tls-and-kedrion-creating-added-value-for-orphan-drugs","status":"publish","type":"news","link":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/","title":{"rendered":"TLS and Kedrion: creating added value for orphan drugs"},"content":{"rendered":"<p>IKOD plant in Siena committed to researching and developing effective therapies to treat particularly rare diseases<br \/>\n<!--more--><\/p>\n<p>At Kedrion Biopharma, we have always focused on the research and develop&shy;ment of plasma-derived orphan drugs in&shy;tended for the treatment of rare diseases. Unmet medical needs led us to establish a plant in Siena, Italy, in 2011. Renamed IKOD (Kedrion Orphan Drugs Plant), these facilities are part of a collaboration between Kedrion Biopharma and Toscana Life Sciences Foundation and, in October 2015, they were granted the authorization to produce biological hemoderived experimen&shy;tal therapies for clinical testing by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA).<\/p>\n<p>In the following video, Lorenzo Terranova, IKOD QA Manager and Qualified Person, tells the story of Kedrion Biopharma&rsquo;s dedication to developing the right treatment for particularly rare diseases.<\/p>\n<p><iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/QRAKnsTslBU?list=PLzJdPX0cqYa2Gu_s7DsKYCJzi3c-ce_rQ\" frameborder=\"0\" allowfullscreen><\/iframe> <\/p>\n","protected":false},"featured_media":0,"template":"","categories_news":[48],"class_list":["post-3879","news","type-news","status-publish","hentry","categories_news-featured-stories"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma\" \/>\n<meta property=\"og:description\" content=\"IKOD plant in Siena committed to researching and developing effective therapies to treat particularly rare diseases\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Kedrion Biopharma\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-08T14:02:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/\",\"url\":\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/\",\"name\":\"TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.kedrion.it\/#website\"},\"datePublished\":\"2017-02-07T23:00:00+00:00\",\"dateModified\":\"2021-03-08T14:02:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.kedrion.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\/\/www.kedrion.it\/news-archive\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"TLS and Kedrion: creating added value for orphan drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.kedrion.it\/#website\",\"url\":\"https:\/\/www.kedrion.it\/\",\"name\":\"Kedrion Biopharma\",\"description\":\"Plasma-Derived Medicinal Products | Keep Life Flowing\",\"publisher\":{\"@id\":\"https:\/\/www.kedrion.it\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.kedrion.it\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.kedrion.it\/#organization\",\"name\":\"Kedrion S.p.A.\",\"url\":\"https:\/\/www.kedrion.it\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg\",\"contentUrl\":\"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg\",\"width\":1772,\"height\":870,\"caption\":\"Kedrion S.p.A.\"},\"image\":{\"@id\":\"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/","og_locale":"en_US","og_type":"article","og_title":"TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma","og_description":"IKOD plant in Siena committed to researching and developing effective therapies to treat particularly rare diseases","og_url":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/","og_site_name":"Kedrion Biopharma","article_modified_time":"2021-03-08T14:02:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/","url":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/","name":"TLS and Kedrion: creating added value for orphan drugs - Kedrion Biopharma","isPartOf":{"@id":"https:\/\/www.kedrion.it\/#website"},"datePublished":"2017-02-07T23:00:00+00:00","dateModified":"2021-03-08T14:02:00+00:00","breadcrumb":{"@id":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.kedrion.it\/en\/tls-and-kedrion-creating-added-value-for-orphan-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.kedrion.it\/en\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.kedrion.it\/news-archive\/"},{"@type":"ListItem","position":3,"name":"TLS and Kedrion: creating added value for orphan drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.kedrion.it\/#website","url":"https:\/\/www.kedrion.it\/","name":"Kedrion Biopharma","description":"Plasma-Derived Medicinal Products | Keep Life Flowing","publisher":{"@id":"https:\/\/www.kedrion.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.kedrion.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.kedrion.it\/#organization","name":"Kedrion S.p.A.","url":"https:\/\/www.kedrion.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg","contentUrl":"https:\/\/www.kedrion.it\/wp-content\/uploads\/2021\/04\/Logo-Kedrion-yellow-1.jpg","width":1772,"height":870,"caption":"Kedrion S.p.A."},"image":{"@id":"https:\/\/www.kedrion.it\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/news\/3879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/media?parent=3879"}],"wp:term":[{"taxonomy":"categories_news","embeddable":true,"href":"https:\/\/www.kedrion.it\/en\/wp-json\/wp\/v2\/categories_news?post=3879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}